相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses
Joseph Sia et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
Karin Lindberg et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
J. Lee et al.
Journal of Thoracic Oncology (2021)
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
Nasser K. Altorki et al.
LANCET ONCOLOGY (2021)
Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer.
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Jacob Sands et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
Hampartsoum B. Barsoumian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer A Phase 2 Clinical Trial
David A. Palma et al.
JAMA ONCOLOGY (2019)
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis
Corey C. Foster et al.
LUNG CANCER (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine
Hiro Sato et al.
CANCER SCIENCE (2019)
PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC
C. Robinson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies
Jie-Tao Ma et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Transcriptome analysis of low-dose ionizing radiation-impacted genes in CD4+ T-cells undergoing activation and regulation of their expression of select cytokines
Seong-Jun Cho et al.
JOURNAL OF IMMUNOTOXICOLOGY (2019)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer
Robert D. Timmerman et al.
JAMA ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline
Gregory M. M. Videtic et al.
PRACTICAL RADIATION ONCOLOGY (2017)
Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance
Daniel E. Spratt et al.
CLINICAL LUNG CANCER (2016)
Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Heike Peulen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing
Sofia R. Gameiro et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies
Jing Zhao et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells
Simon J. Dovedi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer
Kitty Huang et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis
Sashendra Senthi et al.
LANCET ONCOLOGY (2012)
Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure
Nicolaus Andratschke et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implications
Alexander Chi et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Gary M. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
Jean-Yves Douillard et al.
LANCET ONCOLOGY (2006)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
T Winton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
T Le Chevalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Stereotactic radiosurgery for lung tumors: Preliminary report of a phase I trial
RI Whyte et al.
ANNALS OF THORACIC SURGERY (2003)
Extracranial stereotactic radioablation - Results of a phase I study in medically inoperable stage I non-small cell lung cancer
R Timmerman et al.
CHEST (2003)
分享论文
